prostatic cancer (CaP)
Conditions
Interventions
Sponsors
The Fifth Hospital Affiliated to Zhongshan University
Eligibility
Sex/Gender
Male
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age between 18-80 years. 2. PAP expression> 1 + as determined by immunohistochemistry (IHC) in a laboratory accredited by the sponsor; 3. Pathology confirmed prostatic cancer (CaP); 4. Unable to operate or not suitable for surgery patients. 5. According to RECIST 1.1 version of the standard has at least one measles extracranial lesions. 6. Expected survival >= 60 days. 7. The main organs function properly. 8. Hemorrhagic disease or coagulation disorders. 9. Allergy to developer. 10. Participants voluntarily joined the study, signed informed consent, good compliance with follow-up.
Exclusion criteria
Exclusion criteria: 1. T cell transduction efficiency 140 mmHg, diastolic> 90 mmHg), patients with grade I or higher myocardial ischemia or myocardial infarction, grade I and above arrhythmias Including QT interval >= 440ms) or complete cardiac function; 6. Long-term unhealed chest or other parts of the wound or fracture; 7. Those with history of abuse of psychotropic substances who can not be abstinent or who have mental disorders; 8. Past and current patients with objective evidence of a history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-associated pneumonia, severely impaired pulmonary function; 9. There are fungi, bacteria, viruses or other infections that can not be controlled or require antimicrobial treatment. If there is a response to active therapy, a simple urinary tract infection and no complication of bacterial pharyngitis are allowed after consultation with the medical examiner; 10. For subjects with previously used chemotherapy, >= 2 hematologic toxicity or >= 3 non-hematologic toxicity at enrollment according to NCI-CTCAE 4.0 criteria; 11. A known history of HIV or Hepatitis B (HBsAg positive) or Hepatitis C virus (anti-HCV positive) infection is known; 12. There are any indwelling catheters or drains (eg, percutaneous nephrostomy tubes, indwelling Foley catheters, bile ducts, or pleural / peritoneal / pericardial catheters). Allow use of a dedicated central venous catheter; 13. brain metastases; 14. There is a CNS history or disease, such as seizure disease, cerebrovascular ischemia / hemorrhage, dementia, cerebellar disease, or any autoimmune disease involving CNS; 15. There is a significant immunodeficiency; 16. Have a history of severe hypersensitivity reactions to the major therapeutic agents used in this study, including fludarabine, cyclophosphamide, mesna, and tocilizumab and anti-infectives against CRS during pretreatment; 17. There was a history of deep venous thrombosis or pulmonary embolism within the first 6 months of enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PET CT; | — |
Countries
China
Contacts
Public ContactJunjie Mao
Outcome results
None listed